James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
